UBS AG FWP Form Filing by: UBS AG
You will find a link to the attached preliminary price supplement for the above securities and links to the product supplement and accompanying prospectus for the securities under “Additional information about UBS and the securities” in the supplement. preliminary price, which you must read and understand. before investing in the securities.
The issuer has filed a registration statement (including a prospectus supplemented by a product supplement and the preliminary pricing supplement) with the Securities and Exchange Commission (the “SEC”) for the offering to which this communication relates. reports. Before investing, you should read the prospectus accompanying this registration statement and the other documents the issuer has filed with the SEC, including the accompanying preliminary pricing supplement and product supplement, to more complete information about the issuer and this offer. You can obtain these documents for free by visiting EDGAR on the SEC’s website at www.sec.gov. Alternatively, the issuer, any underwriter or dealer participating in the offering will arrange to send you the prospectus if you request it by calling toll-free at 1-833-653-0401. Our central index key, or CIK, on the SEC website is 0001114446.
The risks set out below are discussed in more detail in the “Risk Factors” section of the Preliminary Pricing Supplement. Please consider these risk factors carefully before making an investment decision.
Performance Characteristics Risks
▪The Securities do not guarantee repayment of principal and your investment in the Securities may result in a loss.
▪The contingent payout, if any, is based solely on the closing prices of the underlying shares on the specified determination dates.
▪You will not receive any contingent payment for any period when the closing price of the underlying stock on the determination date is below the downside threshold.
▪Higher contingent payments are generally associated with a higher risk of loss.
▪Investors will not participate in any appreciation of the closing price of the underlying stock and will not have the same rights as the holders of the underlying stock.
Risks related to the characteristics of the underlying shares
▪Individual Stock Risk.
▪There can be no assurance that the prospect of investment implied in the Securities will be successful.
▪No affiliation with the underlying stock issuer.
Estimated Value Considerations
▪The issue price you pay for the securities will exceed their original estimated value.
▪The Initial Estimated Value is a theoretical price and the actual price at which you may be able to sell your Securities in any secondary market (if any) at any time after the Pricing Date may differ from the Initial Estimated Value.
▪Our actual profits may be more or less than the difference between the initial estimated value and the issue price of the securities on the date of pricing.
Risks Related to Liquidity and Secondary Market Pricing Considerations
▪There may be little or no secondary market for the securities.
▪The price at which UBS Securities LLC and its affiliates may offer to purchase the securities in the secondary market (if any) may be higher than UBS’s valuation of the securities at that time, higher than any other secondary market price provided by unaffiliated brokers (if applicable) and, according to your broker, higher than the valuation shown on your client account statements.
▪Prices of securities before maturity.
▪Impact of fees and the use of internal funding rates rather than secondary market credit spreads on secondary market prices.
Risks related to hedging activities and conflicts of interest
▪Potential Conflicts of Interest.
▪The hedging and trading activities of the Calculation Agent and its affiliates may affect the value of the Securities and any amount payable thereon.
▪We may engage in business with or involving the underlying issuer of shares without regard to your interests.
▪Potential impact of UBS on an underlying stock.
▪Following certain events, the Calculation Agent may make adjustments to the underlying equity and terms of the Securities which may adversely affect the market value and yield of the Securities.
Risks related to general credit characteristics
▪Securities are subject to UBS’s credit risk, and any actual or anticipated change in our credit ratings or credit spreads may adversely affect the market value of securities.
▪The securities are not bank deposits.
▪If UBS is in financial difficulty, FINMA has the power to initiate restructuring or liquidation proceedings against UBS and/or to impose protective measures against it, which proceedings or measures may have a material adverse effect on the market conditions and value of UBS. securities and/or UBS’s ability to make payments thereunder.
US Federal Income Tax Risks
▪Uncertain tax treatment. See “Tax Considerations” in the Preliminary Pricing Supplement and “Significant U.S. Federal Income Tax Consequences”, including the section “— Securities Treated as Prepaid Derivatives or Prepaid Futures with Associated Contingent Coupons” , in the accompanying product supplement. You should consult your tax advisor regarding your tax situation.
For more information on the Underlying Stock, including historical performance information, see “Underlying Stock Information” in the Provisional Pricing Supplement.